Patients who have been diagnosed with HER2-positive breast cancer may be eligible for a clinical study led by Baylor College of Medicine. The multi-institutional research will evaluate a new method of treatment that combines HER2-targeted therapies and excludes chemotherapy.
The study is a follow-up to a recent clinical trial that showed HER2-positive breast cancer patients using trastuzumab (Herceptin) and lapatinib (Tykerb) for 12 weeks – without chemotherapy. Patients reportedly showed a significant benefit in the eradication of breast cancer tumors. The data was released in May 2011 by the